Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL864857 | 0.95 | MMP2 (0.35) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL866699 | 0.82 | — | — | |
| SCHEMBL27803073 | 0.69 | MMP2 (0.33) | — | |
| SCHEMBL27866345 | 0.69 | MMP2 (0.35) | — | |
| SCHEMBL14361651 | 0.67 | ELANE (0.35) | OPRM1OPRD1OPRK1OPRL1ELANE | |
| SCHEMBL866534 | 0.67 | — | — | |
| SCHEMBL28177853 | 0.67 | ELANE (0.34) | ELANE | |
| SCHEMBL17532797 | 0.64 | — | — | |
| SCHEMBL14361695 | 0.62 | MMP2 (0.40) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL15578898 | 0.62 | MMP2 (0.40) | OPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2606887-A1 | DIINDOLYLMETHANE, PRECURSOR AND DERIVATIVES THEREOF IN PREPARATION OF MEDICAMENTS FOR TREATING LIVER DISEASES | Nanjing University (CN) | 2013-06-26 | — | — | EP | claimed |
| EP-2314294-A2 | 3,3'-diindolylmethane immune activating compositions | The Regents of The University of California (US) | 2011-04-27 | — | — | EP | claimed |
| US-20060100264-A1 | 3,3'-Diindolylmethane immune activating compositions | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-05-11 | — | — | US | claimed |
| EP-1328513-A2 | DIINDOLYLMETHANE AND C-SUBSTITUTED DIINDOLYLMETHANE COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE CANCERS | The Texas A & M University System (US) | 2003-07-23 | — | — | EP | claimed |
| EP-0971890-B1 | SUBSTITUTED ANALOGS OF INDOLE-3-CARBINOL AND OF DIINDOLYMETHANE AS ANTIESTROGENS | TEXAS A & M UNIV SYS (US) | 2002-11-27 | — | — | EP | claimed |
| US-20020115708-A1 | Diindolylmethane and C-substituted diindolylmethane compositions and methods for the treatment of multiple cancers | TEXAS A&M UNIVERSITY SYSTEM, THE | 2002-08-22 | — | — | US | claimed |
| WO-2002028832-A2 | DIINDOLYLMETHANE AND C-SUBSTITUTED DIINDOLYLMETHANE COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE CANCERS | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2002-04-11 | — | — | WO | claimed |
| EP-0971890-A2 | SUBSTITUTED ANALOGS OF INDOLE-3-CARBINOL AND OF DIINDOLYMETHANE AS ANTIESTROGENS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2000-01-19 | — | — | EP | claimed |
| US-5948808-A | Indole-3-carbinol, diindolylmethane and substituted analogs as antiestrogens | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 1999-09-07 | — | — | US | claimed |
| WO-1998050357-A2 | SUBSTITUTED ANALOGS OF INDOLE-3-CARBINOL AND OF DIINDOLYMETHANE AS ANTIESTROGENS | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 1998-11-12 | — | — | WO | claimed |
| US-20220280479-A1 | SELF-EMULSIFYING FORMULATIONS OF DIM-RELATED INDOLES | BIORESPONSE, L.L.C. | 2022-09-08 | — | — | US | disclosed |
| US-11337961-B2 | Self-emulsifying formulations of DIM-related indoles | BIORESPONSE, L.L.C. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210046046-A1 | SELF-EMULSIFYING FORMULATIONS OF DIM-RELATED INDOLES | BIORESPONSE, L.L.C. | 2021-02-18 | — | — | US | disclosed |
| US-10799479-B2 | Self-emulsifying formulations of DIM-related indoles | BIORESPONSE, L.L.C. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10441569-B2 | Self-emulsifying formulations of DIM-related indoles | BIORESPONSE, L.L.C. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20020115708-A1 | Diindolylmethane and C-substituted diindolylmethane compositions and methods for the treatment of multiple cancers | TEXAS A&M UNIVERSITY SYSTEM, THE | 2002-08-22 | — | — | US | disclosed |
| WO-2002028832-A2 | DIINDOLYLMETHANE AND C-SUBSTITUTED DIINDOLYLMETHANE COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE CANCERS | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2002-04-11 | — | — | WO | disclosed |
| EP-0971890-A2 | SUBSTITUTED ANALOGS OF INDOLE-3-CARBINOL AND OF DIINDOLYMETHANE AS ANTIESTROGENS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2000-01-19 | — | — | EP | disclosed |
| US-5948808-A | Indole-3-carbinol, diindolylmethane and substituted analogs as antiestrogens | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 1999-09-07 | — | — | US | disclosed |
| WO-1998050357-A2 | SUBSTITUTED ANALOGS OF INDOLE-3-CARBINOL AND OF DIINDOLYMETHANE AS ANTIESTROGENS | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280479-A1 | SELF-EMULSIFYING FORMULATIONS OF DIM-RELATED INDOLES | IDO1, IDO2, CYP8B1 | OPRM1 1403/4885OPRD1 561/4885OPRK1 1006/4885 |
| US-20020115708-A1 | Diindolylmethane and C-substituted diindolylmethane compositions and methods for the treatment of multiple cancers | KRAS, VHL, TP53 | OPRM1 830/4885OPRD1 1174/4885OPRK1 860/4885 |
| US-10441569-B2 | Self-emulsifying formulations of DIM-related indoles | IDO1, IDO2, CYP8B1 | OPRM1 1403/4885OPRD1 561/4885OPRK1 1006/4885 |
| US-20060100264-A1 | 3,3'-Diindolylmethane immune activating compositions | CD69, ICOS, CD14 | OPRM1 442/4885OPRD1 351/4885OPRK1 926/4885 |
| US-20210046046-A1 | SELF-EMULSIFYING FORMULATIONS OF DIM-RELATED INDOLES | IDO1, IDO2, CYP8B1 | OPRM1 1214/4885OPRD1 313/4885OPRK1 926/4885 |
| US-11337961-B2 | Self-emulsifying formulations of DIM-related indoles | IDO1, IDO2, CYP8B1 | OPRM1 1214/4885OPRD1 313/4885OPRK1 926/4885 |
| US-10799479-B2 | Self-emulsifying formulations of DIM-related indoles | IDO1, IDO2, CYP8B1 | OPRM1 1214/4885OPRD1 313/4885OPRK1 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.